Mark A. Ritter

6.2k total citations · 1 hit paper
93 papers, 4.6k citations indexed

About

Mark A. Ritter is a scholar working on Pulmonary and Respiratory Medicine, Radiation and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mark A. Ritter has authored 93 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Pulmonary and Respiratory Medicine, 33 papers in Radiation and 20 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mark A. Ritter's work include Prostate Cancer Diagnosis and Treatment (38 papers), Prostate Cancer Treatment and Research (34 papers) and Advanced Radiotherapy Techniques (33 papers). Mark A. Ritter is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (38 papers), Prostate Cancer Treatment and Research (34 papers) and Advanced Radiotherapy Techniques (33 papers). Mark A. Ritter collaborates with scholars based in United States, Canada and Japan. Mark A. Ritter's co-authors include Rick Chappell, Jack Fowler, James E. Cleaver, Cornelius A. Tobias, Wolfgang A. Tomé, Minesh P. Mehta, Paul M. Harari, Seth A. Rosenthal, T. Rockwell Mackie and Jack F. Fowler and has published in prestigious journals such as Nature, Science and Journal of Clinical Oncology.

In The Last Decade

Mark A. Ritter

91 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Is α/β for prostate tumors really low?

2001 507 citations Mark A. Ritter et al. International Journal of Radiation Oncology*Biology*Physics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark A. Ritter United States	34	3.2k	2.6k	1.6k	504	481	93	4.6k
Mark K. Buyyounouski United States	38	4.0k 1.2×	2.2k 0.8×	1.2k 0.8×	581 1.2×	244 0.5×	174	5.0k
Ute Ganswindt Germany	38	2.2k 0.7×	1.3k 0.5×	1.5k 0.9×	477 0.9×	653 1.4×	166	4.4k
Gert De Meerleer Belgium	35	4.4k 1.4×	1.9k 0.7×	1.8k 1.2×	839 1.7×	319 0.7×	168	5.5k
Bernard Dubray France	30	1.6k 0.5×	1.1k 0.4×	1.4k 0.9×	416 0.8×	226 0.5×	119	3.1k
Elisabeth Kjellén Sweden	28	1.5k 0.5×	747 0.3×	909 0.6×	461 0.9×	473 1.0×	120	3.1k
Lawrence R. Coia United States	36	2.8k 0.9×	1.4k 0.5×	1.3k 0.8×	2.2k 4.3×	313 0.7×	87	5.3k
Gregory S. Sibley United States	19	1.5k 0.5×	976 0.4×	999 0.6×	235 0.5×	291 0.6×	41	2.6k
Masato Hareyama Japan	36	3.3k 1.0×	1.8k 0.7×	1.4k 0.9×	1.7k 3.4×	836 1.7×	178	6.2k
Rebecca Paulus United States	34	5.6k 1.8×	2.3k 0.9×	1.9k 1.2×	623 1.2×	506 1.1×	95	7.0k
Gil’ad N. Cohen United States	32	1.9k 0.6×	1.5k 0.6×	563 0.4×	432 0.9×	225 0.5×	135	3.0k

Countries citing papers authored by Mark A. Ritter

Since Specialization

Citations

This map shows the geographic impact of Mark A. Ritter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Ritter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Ritter more than expected).

Fields of papers citing papers by Mark A. Ritter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Ritter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Ritter. The network helps show where Mark A. Ritter may publish in the future.

Co-authorship network of co-authors of Mark A. Ritter

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Ritter. A scholar is included among the top collaborators of Mark A. Ritter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Ritter. Mark A. Ritter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wojcieszynski, Andrzej P., Shuang G. Zhao, Yiqiong Liu, et al.. (2025). Severe Late Toxicities (Grade 3-5) With 13 Years of Follow-up after Hypofractionated Postprostatectomy Radiotherapy. International Journal of Radiation Oncology*Biology*Physics. 123(2). 374–380.

Floberg, John M., Shane A. Wells, R. A. Bayliss, et al.. (2023). Using 18F-DCFPyL Prostate-Specific Membrane Antigen–Directed Positron Emission Tomography/Magnetic Resonance Imaging to Define Intraprostatic Boosts for Prostate Stereotactic Body Radiation Therapy. Advances in Radiation Oncology. 8(5). 101241–101241. 2 indexed citations

Orłowski, Lucjan T., et al.. (2023). Asymmetric responses of equity returns to changes in exchange rates at different market volatility levels. The Journal of Economic Asymmetries. 28. e00336–e00336. 4 indexed citations

Ritter, Mark A., Patrick A. Kupelian, Daniel G. Petereit, et al.. (2020). A Prospective Multi-Institutional Phase I/II Trial of Step-Wise Dose-per-Fraction Escalation in Low and Intermediate Risk Prostate Cancer. Practical Radiation Oncology. 10(5). 345–353. 4 indexed citations

Babaian, Kara N., Matthew Truong, Jeremy Cetnar, et al.. (2012). Analysis of urological procedures in men who died from prostate cancer using a population‐based approach. British Journal of Urology. 111(3b). E65–70. 7 indexed citations

Michalski, Jeff M., C.A. Lawton, Issam El Naqa, et al.. (2009). Development of RTOG Consensus Guidelines for the Definition of the Clinical Target Volume for Postoperative Conformal Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 76(2). 361–368. 285 indexed citations

Schubert, Leah, D Westerly, Wolfgang A. Tomé, et al.. (2009). A Comprehensive Assessment by Tumor Site of Patient Setup Using Daily MVCT Imaging From More Than 3,800 Helical Tomotherapy Treatments. International Journal of Radiation Oncology*Biology*Physics. 73(4). 1260–1269. 78 indexed citations

Lawton, C.A., Jeff M. Michalski, Issam El Naqa, et al.. (2008). RTOG GU Radiation Oncology Specialists Reach Consensus on Pelvic Lymph Node Volumes for High-Risk Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 74(2). 383–387. 317 indexed citations

Lawton, C.A., Jeff M. Michalski, Issam El Naqa, et al.. (2008). Variation in the Definition of Clinical Target Volumes for Pelvic Nodal Conformal Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 74(2). 377–382. 59 indexed citations

10.

Hong, Theodore S., James S. Welsh, Mark A. Ritter, et al.. (2007). Megavoltage Computed Tomography. American Journal of Clinical Oncology. 30(6). 617–623. 26 indexed citations

11.

Gondi, Vinai, Kristin Bradley, Minesh P. Mehta, et al.. (2006). Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non–small-cell lung cancer. International Journal of Radiation Oncology*Biology*Physics. 67(1). 187–195. 81 indexed citations

12.

Hong, Theodore S., et al.. (2006). Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy. Acta Oncologica. 45(6). 717–727. 22 indexed citations

13.

Harari, Paul M., Mark A. Ritter, Daniel G. Petereit, & Minesh P. Mehta. (2003). Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations. Current Problems in Cancer. 28(1). 7–40. 16 indexed citations

14.

Ritter, Mark A., Kennedy W. Gilchrist, Marta Voytovich, Richard J. Chappell, & Bret Verhoven. (2002). The role of p53 in radiation therapy outcomes for favorable-to-intermediate-risk prostate cancer. International Journal of Radiation Oncology*Biology*Physics. 53(3). 574–580. 33 indexed citations

15.

Ritter, Mark A., et al.. (1995). A rationale for fractionation for slowly proliferating tumors such as prostatic adenocarcinoma. International Journal of Radiation Oncology*Biology*Physics. 32(2). 521–529. 44 indexed citations

16.

Ritter, Mark A., et al.. (1994). Tumor cell kinetics using two labels and flow cytometry. Cytometry. 16(1). 49–58. 14 indexed citations

17.

Ritter, Mark A., et al.. (1994). Tumor cell kinetics in mixed populations. Cytometry. 16(2). 118–128. 7 indexed citations

18.

Ritter, Mark A.. (1993). New approaches to cell kinetics in human tumors. Current Problems in Cancer. 17(6). 329–362. 6 indexed citations

19.

Kinsella, Timothy J., Michael N. Gould, Ríona Mulcahy, Mark A. Ritter, & J. F. Fowler. (1991). Keynote address: Integration of cytostatic agents and radiation therapy: A different approach to “proliferating” human tumors. International Journal of Radiation Oncology*Biology*Physics. 20(2). 295–302. 23 indexed citations

20.

Ritter, Mark A., John Nove, & Jerry R. Williams. (1979). The Oxygen Enhancement Ratio for Radiation Lethality in Ataxia Telangiectasia Cells. International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine. 35(3). 281–285. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact